Multivariate predictors of improvement of ≥10% in LVEF at 6 months post BAV | |||
OR | 95% CI | P value | |
LVEF ≤40% at baseline | 26.8 | 3.0–238.2 | <0.01 |
Multivariate predictors of NYHA score improvement of ≥1 at 30 days post BAV | |||
OR | 95% CI | P value | |
NYHA 4 at baseline | 14.2 | 4.4–45.1 | <0.001 |
NYHA 3 at baseline | 4.8 | 2.0–11.4 | <0.001 |
BMI ≥30 kg/m2 | 3.0 | 1.3–6.8 | <0.01 |
Female | 2.1 | 1.0–4.3 | 0.04 |
Indication: bridge-to-TAVI/SAVR | 1.9 | 0.9–3.9 | 0.08 |
Multivariate predictors of 12-month mortality post BAV | |||
OR | 95% CI | P value | |
Active malignancy at baseline | 4.4 | 1.3–15.1 | 0.02 |
Smoking history | 3.3 | 1.3–7.9 | <0.01 |
LVEF ≤30% at baseline | 3.2 | 1.3–7.6 | <0.01 |
Non-elective procedure | 2.3 | 1.0–5.2 | 0.06 |
Indication: destination | 2.2 | 1.0–4.9 | 0.04 |
BMI ≥30 kg/m2 | 0.3 | 0.1–0.9 | 0.03 |
BAV, balloon aortic valvuloplasty; BMI, body mass index; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.